News

The company reported net loss was $2.74m, compared to a net income of $2.15m for the same period in 2009. Mannatech’s loss from operations was $2.8m for the

Belimumab, the first in a new class of drugs called BLyS-specific inhibitors, blocks the binding of soluble BLyS, a B-cell survival factor, to its receptors on B cells.

The patent application ‘Modular Method to Prepare Tetrameric Cytokines with Improved Pharmacokinetics by the Dock-and-Lock (DNL) Technology’ will issue as US Patent no. 7,906,118 on 15 March 2011.

eStudy is a 100% web-based study management platform that iAdvantage Software hosts for BTS at Cegidem/Dendrite’s network operating center in Chesapeake, Virginia. iAdvantage Marketing and Sales Director Diana

KineMed is a biotechnology company specialized in translational and personalized medicine. As per the agreement, KineMed has given license to its technologies to Bristol-Myers Squibb for identifying and

PPD PatientView is a part of PPD Adaptive Solutions, the suite of customizable, flexible and integrated technology solutions that PPD deploys to meet each client’s needs in advancing

BASF is conducting feasibility study to assess the technical, commercial and economic viability of operating a world-scale complex in Brazil. Following the completion of feasibility study, which is

The new production facility will have an initial capacity of 20,000 metric tonnes per year, and will produce high-tech plastics – Durethan and Pocan. To produce Durethan and

This follows the positive opinion on the designation that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency adopted previously in the November 2010 COMP